Steve Barrington

ThinkingNodeLife.ai (TNL) is the first AI Digital Cells Lab that can generate mechanistic digital human cell clones within a few hours using -omics data. This allows the prediction and the understanding of the impacts of molecules or drugs on any human cells of interest. By being able to mechanistically identify novel disease-targets and to simulate each drug in various R&D phases, TNL provides a decisive advantage for developing both first-in-class and best-in-class drugs. This impacts the entire drug R&D value chain in multiple ways. For example, all assets of a pharmaceutical company can be prioritized for early development and existing launched products can be quickly repurposed for new indications. The TNL AI Digital Cells Lab has already proven its effectiveness in serving biopharmaceutical customers, particularly in the realms of cancer and autoimmune diseases. All this is possible based on its novel Generative Distributed Reasoning AI (GDR-AI) that employs Distributed Reasoning AI instead of statistical correlation to generate causal reasoning models. Khai Pham, MD & PhD (AI) (Sorbonne University), is the founder & CEO of TNL. He has been in the AI field for 30 years. Few have worked on unifying AI across different approaches (Machine Learning, Reasoning AI, and Distributed Multi-Agent AI). He is the leading expert in Distributed AI. The first generation of his Distributed AI was used in his first AI company (acq. by Nasdaq: EPNY for $637M). At TNL, he is surrounded by an amazing multi-disciplinary executive team that has been involved in $10+B total exits.